Hepatocellular lipid metabolic machinery

The hepatocellular lipid metabolic machinery refers to the integrated network of enzymes, transporters, and regulatory proteins within hepatocytes that maintain systemic and local lipid homeostasis (NIH, 2023). This system encompasses key pathways such as de novo lipogenesis, fatty acid uptake and oxidation, and the synthesis and secretion of lipoproteins (PubMed, 2021). Dysregulation of this machinery is a central driver in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, non-alcoholic steatohepatitis (NASH), characterized by excessive lipid accumulation and subsequent inflammation (StatPearls, 2024). Therapeutic strategies targeting this machinery involve a diverse range of pharmacological agents, including THR-beta agonists like Resmetirom, FXR agonists like Obeticholic acid, and ACC inhibitors (NEJM, 2024; PubMed, 2022). These drugs aim to restore metabolic balance by either reducing lipid production or increasing lipid clearance and oxidation. Given its complexity, the machinery is not a single drug target but rather a collection of distinct molecular entities that are collectively modulated to treat metabolic and cardiovascular diseases (Nature Reviews Drug Discovery, 2023).

Other names

Hepatic lipid metabolismLiver lipid metabolic pathwaysHepatocyte lipid homeostasis

Drugs targeting this machinery act through various mechanisms including inhibition of de novo lipogenesis (e.g., ACC inhibitors), activation of fatty acid oxidation (e.g., PPAR-alpha agonists), modulation of cholesterol synthesis (e.g., HMG-CoA reductase inhibitors), and regulation of bile acid signaling (e.g., FXR agonists) (PubMed, 2022).